Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8.3% – Still a Buy?

by · The Cerbat Gem

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) was up 8.3% during mid-day trading on Wednesday . The stock traded as high as $20.95 and last traded at $20.9490. Approximately 1,914,459 shares traded hands during trading, a decline of 69% from the average daily volume of 6,214,513 shares. The stock had previously closed at $19.35.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft raised their target price on Sarepta Therapeutics to $12.00 and gave the company a “sell” rating in a report on Friday, August 15th. The Goldman Sachs Group upped their price target on shares of Sarepta Therapeutics to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Wall Street Zen cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus price target of $33.75.

Get Our Latest Stock Report on SRPT

Sarepta Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company has a 50-day moving average of $20.26 and a 200-day moving average of $22.34. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -24.16 and a beta of 0.52.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same quarter last year, the company posted $0.62 EPS. Sarepta Therapeutics’s quarterly revenue was down 14.5% compared to the same quarter last year. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the company. Hurley Capital LLC lifted its stake in shares of Sarepta Therapeutics by 139.2% during the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 835 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $1,458,000. Sound View Wealth Advisors Group LLC lifted its stake in shares of Sarepta Therapeutics by 18.8% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 4,863 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 771 shares during the period. Blueshift Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth $488,000. Finally, Raiffeisen Bank International AG grew its position in shares of Sarepta Therapeutics by 1,092.2% in the first quarter. Raiffeisen Bank International AG now owns 17,465 shares of the biotechnology company’s stock valued at $1,220,000 after purchasing an additional 16,000 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

See Also